



NDA 21-130/S-004  
NDA 21-131/S-004  
NDA 21-132/S-004

Pharmacia & Upjohn Company  
c/o Pfizer Inc.  
Attention: Robert S. Gremban  
Regulatory Affairs Manager  
7000 Portage Road  
Kalamazoo, MI 49001-0199

Dear Mr. Gremban:

Please refer to your supplemental new drug applications dated September 26, 2002, received September 27, 2002, submitted under section 505 (b) of the Federal Food, Drug, and Cosmetic Act for

Zyvox™ Tablets, (linezolid), NDA 21-130/S-004

Zyvox™ IV Injection, (linezolid), NDA 21-131/S-004, and

Zyvox™ for Oral Suspension (linezolid), NDA 21-132/S-004

We acknowledge receipt of your submissions dated November 5 and 21, and December 18, 2002, and January 14 and 31, and April 3, 2003.

These supplemental new drug applications provide for the use of ZYVOX™ Tablets, ZYVOX™ IV Injection, and ZYVOX™ for Oral Suspension for the treatment of diabetic foot infections.

We have completed our review of these applications as amended, and they are approved effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling for the package insert.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplements NDA 21-130/S-004, NDA 21-131/S-004 and NDA 21-132/S-004." Approval of these submissions by FDA is not required before the labeling is used.

FDA's Pediatric Rule [at 21 CFR 314.55/21 CFR 601.27] was challenged in court. On October 17, 2002, the court ruled that FDA did not have the authority to issue the Pediatric Rule and has barred FDA from enforcing it. Although the government decided not to pursue an appeal in the courts, it will work with Congress in an effort to enact legislation requiring pharmaceutical manufacturers to conduct appropriate pediatric clinical trials. In addition, third party interveners have decided to appeal the court's decision striking down the rule. Therefore, we encourage you to submit a pediatric plan that describes development of your product in the pediatric population where it may be used. Please be aware that whether or not this pediatric plan and subsequent

submission of pediatric data will be required depends upon passage of legislation or the success of the third party appeal. In any event, we hope you will decide to submit a pediatric plan and conduct the appropriate pediatric studies to provide important information on the safe and effective use of this drug in the relevant pediatric populations.

The pediatric exclusivity provisions of FDAMA as reauthorized by the Best Pharmaceuticals for Children Act are not affected by the court's ruling. Pediatric studies conducted under the terms of section 505A of the Federal Food, Drug, and Cosmetic Act may result in additional marketing exclusivity for certain products. You should refer to the Guidance for Industry on Qualifying for Pediatric Exclusivity (available on our web site at [www.fda.gov/cder/pediatric](http://www.fda.gov/cder/pediatric)) for details. If you wish to qualify for pediatric exclusivity you should submit a "Proposed Pediatric Study Request". FDA generally does not consider studies submitted to an NDA before issuance of a Written Request as responsive to the Written Request. Applicants should obtain a Written Request before submitting pediatric studies to an NDA.

In addition, submit three copies of the introductory promotional materials that you propose to use for these products. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Anti-Infective Drug Products and two copies of both the promotional materials and the package insert(s) directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Judit Milstein, Regulatory Project Manager, at (301) 827-2207.

Sincerely,

{See appended electronic signature page}

Janice M. Soreth, M.D.  
Director  
Division of Anti-Infective Drug Products  
Office of Drug Evaluation IV  
Center for Drug Evaluation and

Enclosure: Package Insert

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Janice Soreth

7/22/03 03:35:37 PM